Despite significant advances in molecular profiling and treatments for multiple myeloma, patients with high-risk and ultra high-risk disease still have poor outcomes, with variable and unpredictable responses to therapy. The MMRF-CoMMpass study (NCT01454297) is a cooperative research endeavor aiming to map the genomic profile of patients with multiple myeloma to clinical outcomes. Certain features such as loss of P53 and chromosome 1 abnormalities have been associated with high-risk disease. It is important to better characterize multiple myeloma subtypes to advance our understanding of patient responses to therapy and how high-risk features may impact long-term outcomes.

In this exclusive podcast, Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, discusses some of the results from the CoMMpass study, highlighting specific genomic features linked to high-risk and ultra high-risk multiple myeloma. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.

The post MMRF-CoMMpass: the genomic basis of myeloma subtypes appeared first on VJHemOnc.